46817-91-8

• 常用中文名：维洛沙秦
• 常用英文名：2-[(2-ethoxyphenoxy)methyl]morpholine
• CAS号：46817-91-8
• 分子式：C₁₃H₁₉NO₃
• 分子量：237.29500
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 5-HT受体
• 发布时间：2018-04-29 08:00:00
• 更新时间：2024-01-02 14:30:49
• 维洛嗪(维洛嗪)是一种去甲肾上腺素再摄取抑制剂,也是一种有效的5-HT2C激动剂和5-HT2B拮抗剂,其EC50分别为32μM和27μM。维洛嗪的作用机制主要涉及5-羟色胺能和去甲肾上腺素能途径。维洛嗪可用于研究抑郁症[1][2]。

名称

• 中文名: 维洛沙秦
• 英文名: 2-[(2-ethoxyphenoxy)methyl]morpholine
• 中文别名: 2-((2-乙氧基苯氧基)甲基)吗啉
• 英文别名: Emovit; Morpholine,2-((2-ethoxyphenoxy)methyl); Viloxazinum [INN-Latin]; 2-(2-Ethoxy-phenoxymethyl)-morpholine; 2-(o-ethoxyphenoxymethyl)morpholine; viloxazine; Viloxazina [INN-Spanish]; Viloxazin

物化性质

• 密度: 1.061 g/cm3
• 沸点: 350.5ºC at 760 mmHg
• 熔点: 185-186ºC
• 分子式: C₁₃H₁₉NO₃
• 分子量: 237.29500
• 闪点: 144.3ºC
• 精确质量: 237.13600
• PSA: 39.72000
• LogP: 1.78130
• 折射率: 1.499

生物活性

• 描述: 维洛嗪(维洛嗪)是一种去甲肾上腺素再摄取抑制剂,也是一种有效的5-HT2C激动剂和5-HT2B拮抗剂,其EC50分别为32μM和27μM。维洛嗪的作用机制主要涉及5-羟色胺能和去甲肾上腺素能途径。维洛嗪可用于研究抑郁症[1][2]。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体
  研究领域 >> 神经疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体
  信号通路 >> 神经信号通路 >> 5-HT受体
• 靶点:

  Human 5-HT2C Receptor:32 μM (EC50)

  human 5-HT2B Receptor:27 μM (IC50)

• 参考文献:

  [1]. Yu C, et al. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.

  [2]. Pinder RM, et al. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977 Jun;13(6):401-21.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : QE3940000 CHEMICAL NAME : Morpholine, 2-((2-ethoxyphenoxy)methyl)- CAS REGISTRY NUMBER : 46817-91-8 LAST UPDATED : 199403 DATA ITEMS CITED : 5 MOLECULAR FORMULA : C13-H19-N-O3 MOLECULAR WEIGHT : 237.33 WISWESSER LINE NOTATION : T6M DOTJ C1OR BO2 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2 gm/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - ataxia Behavioral - muscle contraction or spasticity REFERENCE : HEPHD2 Handbook of Experimental Pharmacology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.50- 1978- Volume(issue)/page/year: 55,527,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 60 mg/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - ataxia Behavioral - muscle contraction or spasticity REFERENCE : HEPHD2 Handbook of Experimental Pharmacology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.50- 1978- Volume(issue)/page/year: 55,527,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 552 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 27,437,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 60 mg/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - ataxia Behavioral - muscle contraction or spasticity REFERENCE : HEPHD2 Handbook of Experimental Pharmacology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.50- 1978- Volume(issue)/page/year: 55,527,1980 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 130 mg/kg SEX/DURATION : female 8-20 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral REFERENCE : ATSUDG Archives of Toxicology, Supplement. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) No.1- 1978- Volume(issue)/page/year: 7,504,1984

合成路线

47374-79-8 ~98% 46817-91-8

文献：Audouze, Karine; Nielsen, Elsebet stergaard.; Peters, Dan Journal of Medicinal Chemistry, 2004 , vol. 47, # 12 p. 3089 - 3104

35604-67-2 ~% 46817-91-8

文献：Supernus Pharmaceuticals Inc. Patent: US2011/251198 A1, 2011 ; Location in patent: Page/Page column 15 ;

94-71-3 ~% 46817-91-8

文献：Audouze, Karine; Nielsen, Elsebet stergaard.; Peters, Dan Journal of Medicinal Chemistry, 2004 , vol. 47, # 12 p. 3089 - 3104

40987-25-5 ~% 46817-91-8

文献：Audouze, Karine; Nielsen, Elsebet stergaard.; Peters, Dan Journal of Medicinal Chemistry, 2004 , vol. 47, # 12 p. 3089 - 3104

5296-35-5 926-39-6 ~39% 46817-91-8

文献：Supernus Pharmaceuticals Inc. Patent: US2011/251198 A1, 2011 ; Location in patent: Page/Page column 13-14 ;

1338700-16-5 ~% 46817-91-8

文献：Supernus Pharmaceuticals Inc. Patent: US2011/251198 A1, 2011 ;

5296-35-5 ~% 46817-91-8

文献：Supernus Pharmaceuticals Inc. Patent: US2011/251198 A1, 2011 ;

1330189-29-1 ~% 46817-91-8

文献：Letavic, Michael A.; Keith, John M.; Ly, Kiev S.; Bonaventure, Pascal; Feinstein, Mark A.; Lord, Brian; Miller, Kirsten L.; Motley, S. Timothy; Nepomuceno, Diane; Sutton, Steven W.; Carruthers, Nicholas I. Bioorganic and Medicinal Chemistry Letters, 2008 , vol. 18, # 21 p. 5796 - 5799

上下游产品

上游产品  5
35604-67-2 94-71-3 40987-25-5 5296-35-5
926-39-6
下游产品  0